Works matching DE "PROPROTEIN convertases"
Results: 374
Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain.
- Published in:
- PLoS Biology, 2017, v. 15, n. 3, p. 1, doi. 10.1371/journal.pbio.2001882
- By:
- Publication type:
- Article
Do Predictors of Incomplete Kawasaki Disease Exist for Infants?
- Published in:
- Pediatric Cardiology, 2013, v. 34, n. 2, p. 286, doi. 10.1007/s00246-012-0440-3
- By:
- Publication type:
- Article
Genetics: A gene of rare effect.
- Published in:
- Nature, 2013, v. 496, n. 7444, p. 152, doi. 10.1038/496152a
- By:
- Publication type:
- Article
Correlation of serum PCSK9 in CHD patients with the severity of coronary arterial lesions.
- Published in:
- European Review for Medical & Pharmacological Sciences, 2016, v. 20, n. 6, p. 1135
- By:
- Publication type:
- Article
Elevated Circulating PCSK9 Concentrations Predict Subclinical Atherosclerotic Changes in Low Risk Obese and Non-Obese Patients.
- Published in:
- Cardiology & Therapy, 2017, v. 6, n. 2, p. 281, doi. 10.1007/s40119-017-0092-8
- By:
- Publication type:
- Article
Proprotein Convertases and the Complement System.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.958121
- By:
- Publication type:
- Article
Clinical guidance on the contemporary use of proprotein convertase subtilisin/kexin type 9 monoclonal antibodies.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, p. 52, doi. 10.1111/dom.13637
- By:
- Publication type:
- Article
Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, p. 39, doi. 10.1111/dom.13636
- By:
- Publication type:
- Article
PCSK9 inhibitors and diabetes: Translational biology to clinical practice.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 3, p. 451, doi. 10.1111/dom.13600
- By:
- Publication type:
- Article
Islet prohormone processing in health and disease.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, p. 64, doi. 10.1111/dom.13401
- By:
- Publication type:
- Article
Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 6, p. 1479, doi. 10.1111/dom.13257
- By:
- Publication type:
- Article
Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new‐onset diabetes mellitus and glucose metabolism: A systematic review and meta‐analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 6, p. 1391, doi. 10.1111/dom.13235
- By:
- Publication type:
- Article
Plasma proprotein‐convertase‐subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 4, p. 943, doi. 10.1111/dom.13181
- By:
- Publication type:
- Article
Glucagon receptor as a drug target: A witches' brew of eye of newt (peptides) and toe of frog (receptors).
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 2, p. 233, doi. 10.1111/dom.13102
- By:
- Publication type:
- Article
Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 7, p. 989, doi. 10.1111/dom.12909
- By:
- Publication type:
- Article
Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 ( PCSK9) concentrations: a systematic review and meta-analysis of clinical trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 11, p. 1042, doi. 10.1111/dom.12536
- By:
- Publication type:
- Article
A novel method for direct measurement of complement convertases activity in human serum.
- Published in:
- Clinical & Experimental Immunology, 2014, v. 178, n. 1, p. 142, doi. 10.1111/cei.12388
- By:
- Publication type:
- Article
Novel Hypolipidemic Agents: the Role of PCSK9 Inhibitors.
- Published in:
- Hospital Chronicles, 2014, v. 9, p. 129
- By:
- Publication type:
- Article
Secreted protease PRSS35 suppresses hepatocellular carcinoma by disabling CXCL2-mediated neutrophil extracellular traps.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-37227-z
- By:
- Publication type:
- Article
How the prohormone theory solved two important controversies in hormonal and neural peptide biosynthesis.
- Published in:
- Frontiers in Endocrinology, 2013, v. 4, p. 1, doi. 10.3389/fendo.2013.00148
- By:
- Publication type:
- Article
Role of adaptor proteins in secretory granule biogenesis and maturation.
- Published in:
- Frontiers in Endocrinology, 2013, v. 4, p. 1, doi. 10.3389/fendo.2013.00101
- By:
- Publication type:
- Article
The regulated secretory pathway and human disease: insights from gene variants and single nucleotide polymorphisms.
- Published in:
- Frontiers in Endocrinology, 2013, v. 4, p. 1, doi. 10.3389/fendo.2013.00096
- By:
- Publication type:
- Article
Paired Basic Amino Acid-cleaving Enzyme 4 (PCSK6): An Emerging New Target Molecule in Human Melanoma.
- Published in:
- Acta Dermato-Venereologica, 2020, v. 100, n. 5, p. 1, doi. 10.2340/00015555-3525
- By:
- Publication type:
- Article
Vitamin D prohormone in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
- Published in:
- International Journal of Nephrology & Renovascular Disease, 2017, v. 10, p. 109, doi. 10.2147/IJNRD.S97637
- By:
- Publication type:
- Article
PCSK9 rs7552841 is associated with plasma lipids profiles in female Chinese adolescents without posttraumatic stress disorder.
- Published in:
- BioScience Trends, 2017, v. 11, n. 5, p. 542, doi. 10.5582/bst.2017.01264
- By:
- Publication type:
- Article
Furin as a therapeutic target in cystic fibrosis airways disease.
- Published in:
- European Respiratory Review, 2023, v. 32, n. 168, p. 1, doi. 10.1183/16000617.0256-2022
- By:
- Publication type:
- Article
Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders.
- Published in:
- 2016
- By:
- Publication type:
- journal article
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Sodium challenge does not support an acute gastrointestinal-renal natriuretic signaling axis in humans.
- Published in:
- Kidney International, 2012, v. 82, n. 12, p. 1313, doi. 10.1038/ki.2012.269
- By:
- Publication type:
- Article
Case-control study on PCSK9 R496W (rs374603772) and D374Y (rs137852912) mutations in Turkish patients with primary dyslipidemia.
- Published in:
- 2018
- By:
- Publication type:
- Abstract
PCSK 9 gain-of-function mutations (R496W and D374Y) and clinical cardiovascular characteristics in a cohort of Turkish patients with familial hypercholesterolemia.
- Published in:
- Anatolian Journal of Cardiology / Anadolu Kardiyoloji Dergisi, 2017, v. 18, n. 4, p. 266, doi. 10.14744/AnatolJCardiol.2017.7654
- By:
- Publication type:
- Article
Evaluation of cardiac biomarkers and right ventricular dysfunction in patients with acute pulmonary embolism.
- Published in:
- Anatolian Journal of Cardiology / Anadolu Kardiyoloji Dergisi, 2016, v. 16, n. 4, p. 276, doi. 10.5152/akd.2014.5828
- By:
- Publication type:
- Article
Novel insights on the treatment of hypercholesterolemia.
- Published in:
- Expert Review of Endocrinology & Metabolism, 2015, v. 10, n. 3, p. 269, doi. 10.1586/17446651.2015.1033373
- By:
- Publication type:
- Article
Dysregulation of FURIN and Other Proprotein Convertase Genes in the Progression from HPV Infection to Cancer.
- Published in:
- International Journal of Molecular Sciences, 2025, v. 26, n. 2, p. 461, doi. 10.3390/ijms26020461
- By:
- Publication type:
- Article
Therapeutic Targeting of the Proteolytic Enzymes.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 1, p. 521, doi. 10.3390/ijms24010521
- By:
- Publication type:
- Article
Differential Effects of Furin Deficiency on Insulin Receptor Processing and Glucose Control in Liver and Pancreatic β Cells of Mice.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 12, p. 6344, doi. 10.3390/ijms22126344
- By:
- Publication type:
- Article
PCSK9 is Expressed in Human Visceral Adipose Tissue and Regulated by Insulin and Cardiac Natriuretic Peptides.
- Published in:
- International Journal of Molecular Sciences, 2019, v. 20, n. 2, p. 245, doi. 10.3390/ijms20020245
- By:
- Publication type:
- Article
Non-Native Conformational Isomers of the Catalytic Domain of PCSK9 Induce an Immune Response, Reduce Lipids and Increase LDL Receptor Levels.
- Published in:
- International Journal of Molecular Sciences, 2018, v. 19, n. 2, p. 640, doi. 10.3390/ijms19020640
- By:
- Publication type:
- Article
Evolocumab.
- Published in:
- Australian Prescriber, 2016, v. 39, n. 5, p. 180, doi. 10.18773/austprescr.2016.078
- Publication type:
- Article
PCSK9 inhibitors - mechanisms of action.
- Published in:
- Australian Prescriber, 2016, v. 39, n. 5, p. 164, doi. 10.18773/austprescr.2016.060
- By:
- Publication type:
- Article
Cardiovascular Safety of Evolocumab: a Systematic Review and Meta-Analysis.
- Published in:
- 2016
- By:
- Publication type:
- Editorial
PCSK9: the Critical Role of Familial Hypercholesterolemia from Discovery to Benefit for all.
- Published in:
- 2016
- By:
- Publication type:
- Editorial
Erratum to: Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia.
- Published in:
- 2016
- By:
- Publication type:
- Erratum
Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study.
- Published in:
- Cardiovascular Drugs & Therapy, 2016, v. 30, n. 3, p. 297, doi. 10.1007/s10557-016-6655-4
- By:
- Publication type:
- Article
Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia.
- Published in:
- Cardiovascular Drugs & Therapy, 2016, v. 30, n. 3, p. 305, doi. 10.1007/s10557-016-6666-1
- By:
- Publication type:
- Article
PCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a).
- Published in:
- Cardiovascular Drugs & Therapy, 2015, v. 29, n. 3, p. 295, doi. 10.1007/s10557-015-6588-3
- By:
- Publication type:
- Article
Significance of Monoclonal PCSK9-Antibodies - New Approaches to the Therapy of Hypercholesterolemia.
- Published in:
- Blood Purification, 2016, v. 41, n. 4, p. 270, doi. 10.1159/000443140
- By:
- Publication type:
- Article
Association of Level of Proprotein Convertase Subtilisin/Kexin Type 9 with Intima-Media Thickness in Patients with Familial Hypercholesterolemia.
- Published in:
- Bulletin of Experimental Biology & Medicine, 2017, v. 163, n. 2, p. 199, doi. 10.1007/s10517-017-3765-3
- By:
- Publication type:
- Article
Cleavage activates Dispatched for Sonic Hedgehog ligand release.
- Published in:
- eLife, 2018, p. 1, doi. 10.7554/eLife.31678
- By:
- Publication type:
- Article